Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) – Research analysts at Leerink Swann issued their Q3 2017 earnings per share (EPS) estimates for shares of Nightstar Therapeutics PLC Sponsored ADR in a report released on Monday. Leerink Swann analyst J. Schwartz forecasts that the company will post earnings per share of ($0.12) for the quarter. Leerink Swann currently has a “Outperform” rating and a $25.00 target price on the stock. Leerink Swann also issued estimates for Nightstar Therapeutics PLC Sponsored ADR’s Q4 2017 earnings at ($0.17) EPS, FY2017 earnings at ($0.70) EPS, FY2018 earnings at ($1.30) EPS and FY2019 earnings at ($1.27) EPS.

ILLEGAL ACTIVITY NOTICE: “Nightstar Therapeutics PLC Sponsored ADR Expected to Earn Q3 2017 Earnings of ($0.12) Per Share (NITE)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/25/nightstar-therapeutics-plc-sponsored-adr-expected-to-earn-q3-2017-earnings-of-0-12-per-share-nite.html.

Several other brokerages also recently weighed in on NITE. Wedbush assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating and a $19.00 target price on the stock. Jefferies Group LLC assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set a “buy” rating and a $25.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on Nightstar Therapeutics PLC Sponsored ADR in a research note on Monday. They set an “outperform” rating and a $30.00 target price on the stock.

Shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) opened at 18.77 on Wednesday. Nightstar Therapeutics PLC Sponsored ADR has a 52 week low of $14.56 and a 52 week high of $24.93. The stock’s market capitalization is $527.46 million. The stock’s 50 day moving average is $18.94 and its 200 day moving average is $18.94.

An institutional investor recently bought a new position in Nightstar Therapeutics PLC Sponsored ADR stock. Nationwide Fund Advisors bought a new position in shares of Nightstar Therapeutics PLC Sponsored ADR (NASDAQ:NITE) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 62,300 shares of the company’s stock, valued at approximately $1,196,000. Nationwide Fund Advisors owned about 0.22% of Nightstar Therapeutics PLC Sponsored ADR at the end of the most recent reporting period.

About Nightstar Therapeutics PLC Sponsored ADR

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases.

Receive News & Ratings for Nightstar Therapeutics PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.